U.S. FDA extends review of Pfizer's experimental skin disease drug

[April 07, 2021]  (Reuters) - Pfizer Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had extended its review of the company's experimental treatment for atopic dermatitis by three months.

The company did not disclose the FDA's reason for the extension.

(Reporting by Manas Mishra in Bengaluru; Editing by Devika Syamnath)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content